• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲对乳腺 X 光筛查的宣传观点。

The European advocacy perspective on mammography screening.

机构信息

EUROPA DONNA-The European Breast Cancer Coalition, Head Office, Piazza Amendola 3, Milan, Italy.

出版信息

Breast. 2011 Feb;20(1):93-5. doi: 10.1016/j.breast.2010.07.003. Epub 2010 Aug 12.

DOI:10.1016/j.breast.2010.07.003
PMID:20708405
Abstract

Controversy and publicity about the value of mammography screening programs continue in Europe and across the globe. As Europe's breast cancer advocacy organisation, Europa Donna-The European Breast Cancer Coalition advocates for mammography screening as one of the essential services to which all women should have access, stipulating, however, that mammography screening programs must be set up and carried out in accordance with the European Guidelines for quality assurance in breast cancer screening and diagnosis. Europa Donna's involvement and history in following programs and progress in this area is extensive and dates back to 2001. The communication process for women eligible for screening is complicated and needs to be addressed appropriately in every country. However, the position of our organisation remains unchanged: Mammography screening carried out according to EU Guidelines is the best form of early detection available today and the scientific evidence shows that it improves mortality rates from the disease.

摘要

在欧洲和全球范围内,有关乳房 X 光筛查计划价值的争议和宣传仍在继续。作为欧洲乳腺癌倡导组织,欧洲抗癌组织(Europa Donna-The European Breast Cancer Coalition)主张将乳房 X 光筛查作为所有女性都应获得的基本服务之一,但规定乳房 X 光筛查计划必须按照欧洲乳腺癌筛查和诊断质量保证指南进行设立和实施。Europa Donna 在这一领域的参与和历史可以追溯到 2001 年,涉及到该领域的项目和进展非常广泛。适合筛查的女性的沟通流程非常复杂,在每个国家都需要得到妥善处理。然而,我们组织的立场保持不变:根据欧盟指南进行的乳房 X 光筛查是目前可用的最佳早期检测形式,科学证据表明它可以降低该疾病的死亡率。

相似文献

1
The European advocacy perspective on mammography screening.欧洲对乳腺 X 光筛查的宣传观点。
Breast. 2011 Feb;20(1):93-5. doi: 10.1016/j.breast.2010.07.003. Epub 2010 Aug 12.
2
The European patient advocacy perspective on specialist breast units and accreditation.欧洲患者权益倡导者对乳腺专科单位及认证的看法。
Breast. 2015 Jun;24(3):287-9. doi: 10.1016/j.breast.2015.01.013. Epub 2015 Feb 18.
3
[Breast cancer screening: current status].[乳腺癌筛查:现状]
Radiologia. 2013 Jul-Aug;55(4):305-14. doi: 10.1016/j.rx.2012.05.003. Epub 2012 Aug 28.
4
Promotion of quality-controlled mammography alone as a screening modality in Japan.在日本,仅推广质量控制的乳腺钼靶摄影作为一种筛查方式。
Breast Cancer. 2014 Jul;21(4):435-41. doi: 10.1007/s12282-012-0410-x. Epub 2012 Oct 23.
5
First report of introducing population-based breast cancer screening in Poland: experience of the 3-million population region of Lower Silesia.波兰首次引入基于人群的乳腺癌筛查报告:下西里西亚 300 万人口地区的经验。
Cancer Epidemiol. 2011 Dec;35(6):e111-5. doi: 10.1016/j.canep.2011.01.011. Epub 2011 Aug 15.
6
Screening mammography: the goal is changing.乳腺筛查钼靶检查:目标正在改变。
Am Fam Physician. 2013 Feb 15;87(4):246-7.
7
Screening mammography and the "r" word.乳腺钼靶筛查与“召回”一词
N Engl J Med. 2009 Dec 24;361(26):2501-3. doi: 10.1056/NEJMp0911447. Epub 2009 Nov 25.
8
Screening mammography--early detection or over-diagnosis? Contribution from Australian data.乳腺钼靶筛查——早期发现还是过度诊断?来自澳大利亚数据的贡献。
Climacteric. 2014 Dec;17 Suppl 2:66-72. doi: 10.3109/13697137.2014.956718. Epub 2014 Sep 16.
9
Breast cancer screening: why, when, and how many?乳腺癌筛查:为何、何时以及筛查多少人?
Clin Obstet Gynecol. 2011 Mar;54(1):125-32. doi: 10.1097/GRF.0b013e318208020d.
10
[Assessment of mammography screening and its introduction in Germany in the Statutory Early Diagnosis Program].[乳腺X线筛查评估及其在德国法定早期诊断计划中的引入]
Zentralbl Gynakol. 1999;121(3):159-65.

引用本文的文献

1
Evolution of mammographic image quality in the state of Rio de Janeiro.里约热内卢州乳腺钼靶图像质量的演变
Radiol Bras. 2015 Mar-Apr;48(2):86-92. doi: 10.1590/0100-3984.2014.0047.